Research Signal – Source date 2022-07-15
A substance from a poisonous beetle can be a starting point for a drug candidate without making the original material a treatment. A 2022 review of animal-derived traditional Chinese medicinal materials makes that distinction especially clear through cantharidin and norcantharidin: cantharidin is a toxic compound from the Chinese blister beetle, while norcantharidin is a modified compound developed to reduce some of cantharidin’s harmful effects. The review describes experiments on norcantharidin in breast cancer cells, but this history does not show that it is safe or effective for people with breast cancer.
The review brings together very different materials: a fungus associated with insect larvae, compounds from toad secretion, bee venom, and other animal-derived substances. Its evidence ranges from breast cancer cells grown in the laboratory to mouse models. Those experiments offer clues about biological activity, but they measure different things and sit far upstream of a demonstrated treatment benefit for patients.
A source material is not the same as a drug candidate
Cantharidin illustrates why researchers may isolate or modify a substance rather than test the original material as a medicine. The review describes cantharidin as both the main active ingredient and a toxic component of the Chinese blister beetle. Its effects on cancer cells have drawn interest, but its reported adverse effects include severe digestive irritation and urinary toxicity, with kidney failure among the possible harms. These concerns have greatly limited its clinical use.
Norcantharidin, often shortened to NCTD, is a small synthetic compound that can also be obtained from cantharidin. Removing two methyl groups from cantharidin’s chemical structure was intended to lessen toxicity. The review notes that NCTD has been used as an anticancer drug in China, and discusses its breast cancer cell research separately from the original beetle compound. That distinction matters: changing a molecule may change its properties, but the review does not establish a safe breast cancer dose or patient benefit for NCTD.
This same care with identity applies to the other materials. Ophiocordyceps sinensis, commonly called Chinese caterpillar fungus, is a fungus that grows in association with insect larvae. Researchers have tested cordycepin, a specific molecule found in extracts of the fungus, as well as water-based and alcohol-based extracts and a cultivated fungal substitute. Toad secretion, called Chansu in the review, contains several types of compounds; the research discussed there has focused particularly on bufadienolides, including bufalin. Bee venom is a mixture of peptides, enzymes and other substances, not a single defined ingredient.
Cell effects and mouse findings answer different questions
Cordycepin reduced the viability of MCF-7 breast cancer cells in a laboratory experiment. The review gives an IC50 value of 9.58 micromoles per liter. In plain terms, under those experimental conditions, that concentration corresponded to a 50 percent reduction in the measured cell-viability signal. Other cell studies described in the review linked cordycepin exposure with cell death or sustained cell-cycle arrest, but a dish of cells cannot show how a substance would behave throughout a human body.
A separate line of work tested Hirsutella sinensis, a cultivated fungus used as a substitute for natural Chinese caterpillar fungus, in mice with breast cancer. The review describes reduced tumor growth and less spread to the lungs in that model. It also discusses changes in immune-cell activity. This is a different kind of observation from cordycepin’s effect on MCF-7 cells: the mouse experiment measured tumor growth and spread in a living animal, while the cell study measured viability in a laboratory-grown cancer-cell line. Neither result establishes improved outcomes in people.
The difference also cautions against transferring a result from one form to another. A finding for purified cordycepin does not establish the effect of the whole fungus or its extracts. Likewise, a mouse result for a cultivated substitute cannot automatically be attributed to natural caterpillar fungus or to every constituent it contains.
Combinations may change how cancer cells respond
Some experiments in the review asked whether adding a candidate compound could alter the effect of an established chemotherapy drug in cancer cells. In one breast cancer cell experiment, bufalin from Chansu was tested with paclitaxel. The reported apoptotic fraction—the share of cells undergoing programmed cell death—rose from 12.5 percent with paclitaxel alone to 23.7 percent with 10 nanomoles per liter of bufalin plus 40 nanomoles per liter of paclitaxel. The review describes the combination as having a synergistic effect in that experiment.
That is a measured cell response at specified experimental concentrations. It does not show that adding bufalin would improve chemotherapy for patients, identify a clinically appropriate dose, or establish an acceptable level of harm. Chansu compounds can be highly toxic; the review highlights concerns including disrupted heart rhythm, reduced blood flow to tissues and inadequate oxygen supply. A stronger effect in a cell experiment must be considered alongside toxicity and the difficulty of controlling the dose and composition of the material.
The review also describes NCTD experiments involving drug resistance in breast cancer cells. In those experiments, NCTD was associated with reduced resistance to doxorubicin and vinorelbine in breast cancer cells, alongside lower expression of a protein linked to drug resistance. This is a proposed mechanism in cells, not evidence that NCTD reverses treatment resistance in patients. The combination idea is notable because it asks whether a candidate could change how cancer cells respond to another drug, but that possibility still needs testing at the levels of dose, safety and clinical outcomes.
Complex mixtures make consistency a central problem
Knowing which substance was tested is only part of the challenge. Chansu has a complex chemical composition, and the review says research has concentrated on bufadienolides without establishing how much each component contributes to the overall effects. It calls for more reliable identification and measurement of the active ingredients, as well as better control of toxicity. If the proportions of compounds vary, researchers may not be comparing the same material from one preparation to another.
Bee venom poses a related but distinct problem. Melittin, a peptide in the venom, has received substantial attention, while the actions and metabolism of other components—including enzymes and other peptides—are less well understood in the breast cancer research discussed. The review also notes that clinical studies of adverse effects, doses and forms of administration need more careful assessment. Studying one venom component cannot establish the effects of the full mixture.
The authors point to chemical fingerprinting and quantitative analysis as ways to identify and measure components more consistently. They also call for deeper study of how the constituents act, including through multi-omics approaches that examine biological changes across genes, proteins and metabolites. These steps could make results easier to reproduce and help researchers distinguish a useful compound from a hazardous or inconsistent mixture. Better delivery methods are another research need the review raises, with the aim of improving stability and limiting toxic effects.
The evidence is uneven across the materials
The breadth of the review should not be mistaken for equal evidence behind every candidate. For cordycepin and bufalin, the authors discuss specific breast cancer cell experiments; the caterpillar-fungus substitute has a mouse-model finding. By contrast, they describe deer antler as having no in-depth breast cancer studies of its effects or active components, alongside unresolved questions about composition and quality control.
Oyster provides a different early example: a compound isolated from eastern oyster was reported to affect breast cancer cell lines through effects involving blood-vessel formation, cell death and movement. The review says in-depth research on oyster extracts or their active ingredients in breast cancer remains limited. These examples show why appearing in the same review does not mean that each material has comparable evidence, or that traditional use demonstrates cancer-treatment efficacy.
The review’s overall case is therefore a research opportunity rather than a treatment claim. It gathers earlier laboratory and animal findings, while identifying the need for standardized compounds, clearer toxicity profiles, more reliable delivery and large clinical trials. Those requirements are especially important when the candidate begins as a potent or chemically variable animal-derived substance.
Where this research could lead
For someone whose breast cancer eventually resists an established drug, a precisely formulated compound might one day offer an additional option for an oncology team to evaluate alongside existing care. The experiments described here provide an early rationale for that possibility: some isolated constituents affected cancer cells, and some combinations changed cell-death or drug-resistance measures. Getting from those findings to a patient-level option would require researchers to identify and standardize the active compound, find a way to deliver it, control its toxicity and test it in people.
A well-designed breast cancer trial of a standardized candidate that reports both treatment outcomes and adverse effects would be a meaningful sign of progress toward that future. It would not itself make the candidate an established treatment, but it could show whether the laboratory promise survives careful testing in patients. In 2022, the review described these materials as candidates for further study; it did not place them alongside the treatments already used for breast cancer.
Key Sources
- Primary source: Bioactive constituents of animal-derived traditional Chinese medicinal materials for breast cancer: opportunities and challenges.
DOI or Journal Page · Review or Meta-Analysis · 2022-07-15
Keep exploring